Comprehensive Anaemia Programme and Personalized Therapies (CAPPT): protocol for a cluster-randomised controlled trial testing the effect women's groups, home counselling and iron supplementation on haemoglobin in pregnancy in southern Nepal.

Anaemia Cluster randomised controlled trial Community-intervention Haemoglobin Home visiting Menstrual monitoring Nepal Participatory Learning and Action Pregnant woman

Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
01 Mar 2022
Historique:
received: 24 05 2021
accepted: 19 01 2022
entrez: 2 3 2022
pubmed: 3 3 2022
medline: 4 3 2022
Statut: epublish

Résumé

Anaemia in pregnancy remains prevalent in Nepal and causes severe adverse health outcomes. This non-blinded cluster-randomised controlled trial in the plains of Nepal has two study arms: (1) Control: routine antenatal care (ANC); (2) Home visiting, iron supplementation, Participatory Learning and Action (PLA) groups, plus routine ANC. Participants, including women in 54 non-contiguous clusters (mean 2582; range 1299-4865 population) in Southern Kapilbastu district, are eligible if they consent to menstrual monitoring, are resident, married, aged 13-49 years and able to respond to questions. After 1-2 missed menses and a positive pregnancy test, consenting women < 20 weeks' gestation, who plan to reside locally for most of the pregnancy, enrol into trial follow-up. Interventions comprise two home-counselling visits (at 12-21 and 22-26 weeks' gestation) with iron folic acid (IFA) supplement dosage tailored to women's haemoglobin concentration, plus monthly PLA women's group meetings using a dialogical problem-solving approach to engage pregnant women and their families. Home visits and PLA meetings will be facilitated by auxiliary nurse midwives. The hypothesis is as follows: Haemoglobin of women at 30 ± 2 weeks' gestation is ≥ 0.4 g/dL higher in the intervention arm than in the control. A sample of 842 women (421 per arm, average 15.6 per cluster) will provide 88% power, assuming SD 1.2, ICC 0.09 and CV of cluster size 0.27. Outcomes are captured at 30 ± 2 weeks gestation. Primary outcome is haemoglobin concentration (g/dL). Secondary outcomes are as follows: anaemia prevalence (%), mid-upper arm circumference (cm), mean probability of micronutrient adequacy (MPA) and number of ANC visits at a health facility. Indicators to assess pathways to impact include number of IFA tablets consumed during pregnancy, intake of energy (kcal/day) and dietary iron (mg/day), a score of bioavailability-enhancing behaviours and recall of one nutrition knowledge indicator. Costs and cost-effectiveness of the intervention will be estimated from a provider perspective. Using constrained randomisation, we allocated clusters to study arms, ensuring similarity with respect to cluster size, ethnicity, religion and distance to a health facility. Analysis is by intention-to-treat at the individual level, using mixed-effects regression. Findings will inform Nepal government policy on approaches to increase adherence to IFA, improve diets and reduce anaemia in pregnancy. ISRCTN 12272130 .

Sections du résumé

BACKGROUND BACKGROUND
Anaemia in pregnancy remains prevalent in Nepal and causes severe adverse health outcomes.
METHODS METHODS
This non-blinded cluster-randomised controlled trial in the plains of Nepal has two study arms: (1) Control: routine antenatal care (ANC); (2) Home visiting, iron supplementation, Participatory Learning and Action (PLA) groups, plus routine ANC. Participants, including women in 54 non-contiguous clusters (mean 2582; range 1299-4865 population) in Southern Kapilbastu district, are eligible if they consent to menstrual monitoring, are resident, married, aged 13-49 years and able to respond to questions. After 1-2 missed menses and a positive pregnancy test, consenting women < 20 weeks' gestation, who plan to reside locally for most of the pregnancy, enrol into trial follow-up. Interventions comprise two home-counselling visits (at 12-21 and 22-26 weeks' gestation) with iron folic acid (IFA) supplement dosage tailored to women's haemoglobin concentration, plus monthly PLA women's group meetings using a dialogical problem-solving approach to engage pregnant women and their families. Home visits and PLA meetings will be facilitated by auxiliary nurse midwives. The hypothesis is as follows: Haemoglobin of women at 30 ± 2 weeks' gestation is ≥ 0.4 g/dL higher in the intervention arm than in the control. A sample of 842 women (421 per arm, average 15.6 per cluster) will provide 88% power, assuming SD 1.2, ICC 0.09 and CV of cluster size 0.27. Outcomes are captured at 30 ± 2 weeks gestation. Primary outcome is haemoglobin concentration (g/dL). Secondary outcomes are as follows: anaemia prevalence (%), mid-upper arm circumference (cm), mean probability of micronutrient adequacy (MPA) and number of ANC visits at a health facility. Indicators to assess pathways to impact include number of IFA tablets consumed during pregnancy, intake of energy (kcal/day) and dietary iron (mg/day), a score of bioavailability-enhancing behaviours and recall of one nutrition knowledge indicator. Costs and cost-effectiveness of the intervention will be estimated from a provider perspective. Using constrained randomisation, we allocated clusters to study arms, ensuring similarity with respect to cluster size, ethnicity, religion and distance to a health facility. Analysis is by intention-to-treat at the individual level, using mixed-effects regression.
DISCUSSION CONCLUSIONS
Findings will inform Nepal government policy on approaches to increase adherence to IFA, improve diets and reduce anaemia in pregnancy.
TRIAL REGISTRATION BACKGROUND
ISRCTN 12272130 .

Identifiants

pubmed: 35232469
doi: 10.1186/s13063-022-06043-z
pii: 10.1186/s13063-022-06043-z
pmc: PMC8886560
doi:

Substances chimiques

Hemoglobins 0
Iron, Dietary 0
Iron E1UOL152H7

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

183

Subventions

Organisme : Medical Research Council
ID : MR/R020485/1
Pays : United Kingdom
Organisme : Medical Research Foundation
ID : MR/R020485/1

Informations de copyright

© 2022. The Author(s).

Références

Am J Clin Nutr. 2016 Feb;103(2):495-504
pubmed: 26739036
Int J Gynaecol Obstet. 2007 Aug;98(2):124-8
pubmed: 17585914
Public Health Nutr. 2018 Feb;21(2):377-384
pubmed: 29032790
J Nutr. 2012 Feb;142(2):358-62
pubmed: 22190028
Indian J Pediatr. 2006 Aug;73(8):687-92
pubmed: 16936363
Mutat Res Rev Mutat Res. 2018 Jul - Sep;777:52-63
pubmed: 30115430
Trials. 2018 Mar 9;19(1):176
pubmed: 29523173
Nutrients. 2016 Nov 02;8(11):
pubmed: 27827838
Paediatr Perinat Epidemiol. 2012 Jul;26 Suppl 1:191-204
pubmed: 22742611
Lancet Diabetes Endocrinol. 2019 Mar;7(3):200-212
pubmed: 30733182
J Epidemiol Community Health. 2016 Jul;70(7):663-70
pubmed: 26739272
Health Educ Q. 1988 Winter;15(4):379-94
pubmed: 3230016
Kathmandu Univ Med J (KUMJ). 2016 Oct.-Dec.;14(56):311-317
pubmed: 29336417
Public Health Nutr. 2016 Oct;19(14):2495-507
pubmed: 26996822
Lancet. 2013 May 18;381(9879):1736-46
pubmed: 23683640
Lancet. 2018 Jan 13;391(10116):155-167
pubmed: 28774421
Nutrients. 2017 Oct 05;9(10):
pubmed: 28981457
Int J Gynaecol Obstet. 2000 Jun;69(3):215-22
pubmed: 10854862
Lancet. 2008 Jan 19;371(9608):243-60
pubmed: 18207566
BMJ Glob Health. 2020 Dec;5(12):
pubmed: 33328198
Cochrane Database Syst Rev. 2015 Jul 22;(7):CD004736
pubmed: 26198451
World Health Stat Q. 1985;38(3):302-16
pubmed: 3878044
J Am Diet Assoc. 2010 Jun;110(6):879-91
pubmed: 20497777
Lancet Planet Health. 2021 May;5(5):e263-e276
pubmed: 33811818
Public Health Nutr. 2015 Dec;18(17):3201-10
pubmed: 25824344
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
Int Health. 2010 Mar;2(1):25-35
pubmed: 24037047
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Nutr Rev. 2011 Dec;69(12):693-719
pubmed: 22133195
Br J Haematol. 2017 Jun;177(6):878-883
pubmed: 28397964
Eur J Clin Nutr. 2006 Apr;60(4):469-77
pubmed: 16391580
Lancet. 2010 Apr 3;375(9721):1182-92
pubmed: 20207411
J Biosoc Sci. 2012 Jul;44(4):401-15
pubmed: 22424573
Am J Clin Nutr. 2008 Aug;88(2):324-32
pubmed: 18689367
Matern Child Nutr. 2021 Jul;17 Suppl 1:e13170
pubmed: 34241951
J Nutr. 2005 May;135(5):1106-12
pubmed: 15867289
Soc Sci Med. 1991;33(10):1141-54
pubmed: 1767284
J Nutr. 2009 Mar;139(3):594-7
pubmed: 19158229
JAMA Pediatr. 2013 Sep;167(9):816-25
pubmed: 23689475
Eur J Clin Nutr. 2000 Jan;54(1):3-8
pubmed: 10694764
BMC Pregnancy Childbirth. 2012 Jan 24;12:5
pubmed: 22273440
Soc Sci Med. 2012 Aug;75(4):612-21
pubmed: 22541798
Glob Food Sec. 2018 Jun;17:172-185
pubmed: 29930896
J Obstet Gynaecol Res. 2009 Jun;35(3):459-66
pubmed: 19527383
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Lancet Glob Health. 2013 Jul;1(1):e16-25
pubmed: 25103581
J Nutr. 2018 Sep 1;148(9):1472-1483
pubmed: 30053188
Ann N Y Acad Sci. 2019 Aug;1450(1):15-31
pubmed: 31008520
JNMA J Nepal Med Assoc. 2016 Jan-Mar;54(201):29-32
pubmed: 27935908
BMJ. 2018 Aug 1;362:k3165
pubmed: 30068664
PLoS One. 2019 Jun 12;14(6):e0218288
pubmed: 31188883
Lancet Glob Health. 2016 Feb;4(2):e119-28
pubmed: 26823213
Lancet. 2004 Sep 11-17;364(9438):970-9
pubmed: 15364188
Annu Rev Nutr. 2004;24:105-31
pubmed: 15189115
Nutrients. 2016 Jun 22;8(6):
pubmed: 27338469
Lancet Glob Health. 2017 Oct;5(10):e1004-e1016
pubmed: 28911749
Eur J Clin Nutr. 2018 Nov;72(11):1524-1536
pubmed: 29358603
Eur J Clin Nutr. 2007 Feb;61(2):262-9
pubmed: 16929243
Hematol Oncol Clin North Am. 2016 Apr;30(2):247-308
pubmed: 27040955
J Nutr. 2006 Sep;136(9):2399-404
pubmed: 16920861
Acta Obstet Gynecol Scand. 2000 May;79(5):341-9
pubmed: 10830759
Public Health Nutr. 2018 Feb;21(2):260-272
pubmed: 28854993
PLoS One. 2018 Nov 2;13(11):e0206928
pubmed: 30388173
Lancet Glob Health. 2018 May;6(5):e548-e554
pubmed: 29571592
Br J Nutr. 2014 Jul 14;112(1):132-41
pubmed: 24708993
Hematology Am Soc Hematol Educ Program. 2015;2015:8-13
pubmed: 26637694
BMC Res Notes. 2019 Mar 12;12(1):127
pubmed: 30867036
Blood. 2014 Jan 30;123(5):615-24
pubmed: 24297872
PLoS One. 2015 Feb 20;10(2):e0117383
pubmed: 25700159
BMC Public Health. 2015 Apr 12;15:374
pubmed: 25887449
Lancet. 2008 Sep 13;372(9642):962-71
pubmed: 18790319
Public Health Nutr. 2017 Aug;20(11):1928-1940
pubmed: 28629489
BMJ. 2013 Jun 21;346:f3443
pubmed: 23794316
PLoS One. 2018 May 9;13(5):e0194064
pubmed: 29742136
Soc Sci Med. 1997 Jun;44(11):1739-49
pubmed: 9178416
Lancet. 2013 May 18;381(9879):1721-35
pubmed: 23683639
Biometrics. 2009 Dec;65(4):1003-10
pubmed: 19302405
Trans R Soc Trop Med Hyg. 2000 Sep-Oct;94(5):477-83
pubmed: 11132370

Auteurs

Naomi M Saville (NM)

Institute for Global Health, University College London (UCL), London, UK. n.saville@ucl.ac.uk.

Chandani Kharel (C)

HERD International, Thapathali, Kathmandu, Nepal.

Joanna Morrison (J)

Institute for Global Health, University College London (UCL), London, UK.

Helen Harris-Fry (H)

Department of Population Health, London School of Hygiene & Tropical Medicine (LSHTM), London, UK.

Philip James (P)

Department of Population Health, London School of Hygiene & Tropical Medicine (LSHTM), London, UK.

Andrew Copas (A)

Institute for Global Health, University College London (UCL), London, UK.

Santosh Giri (S)

HERD International, Thapathali, Kathmandu, Nepal.

Abriti Arjyal (A)

HERD International, Thapathali, Kathmandu, Nepal.

B James Beard (BJ)

, Guildford, GU1 3LD, UK.

Hassan Haghparast-Bidgoli (H)

Institute for Global Health, University College London (UCL), London, UK.

Jolene Skordis (J)

Institute for Global Health, University College London (UCL), London, UK.

Adam Richter (A)

Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Sushil Baral (S)

HERD International, Thapathali, Kathmandu, Nepal.
Health Research and Social Development Forum (HERD), Kathmandu, Nepal.

Sara Hillman (S)

Institute for Women's Health, University College London (UCL), London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH